Skip to content
Advertisement
OpenAI introduces MedChemBench to test AI on medicinal chemistry

OpenAI introduces MedChemBench to test AI on medicinal chemistry

OpenAI official logo (public domain, Wikimedia Commons) — CryptoBriefing brand treatment

The benchmark measures how well models handle drug discovery tasks, and even the top scorers are landing below 50%

OpenAI has introduced MedChemBench, a benchmark built to measure how well AI models handle the work of medicinal chemistry. The best score on its leaderboard is 49.7%.

What MedChemBench actually tests

Medicinal chemistry is the discipline of designing and refining molecules that could become drugs.

MedChemBench breaks that work into the kinds of tasks a chemist handles day to day. The benchmark covers interpreting chemical structures, predicting how potent or toxic a compound might be, choosing which candidate molecules to pursue, and mapping out routes to synthesize them.

The research describes MedChemBench as an internal benchmark. In practice, that makes it a yardstick OpenAI uses to evaluate and refine its own models over time.

Advertisement

The leaderboard, and why sub-50% matters

As of late November 2026, OpenAI’s own models sit at the top of the MedChemBench leaderboard. GPT-6 Astra posted a score of 49.7%, while GPT-5.6 Sol came in at 48.3%.

The more telling detail is the ceiling. Neither model clears half the benchmark, which the research attributes to persistent difficulty with consistent multi-step chemical reasoning.

Part of a growing benchmark family

MedChemBench does not stand alone. OpenAI has also built LifeSciBench, which launched around June 2026 and includes 750 expert-authored tasks spread across seven workflows.

The company also has GeneBench, which extends its evaluation work further into the life sciences.

A model called GPT-Rosalind has been run through these benchmarks. According to the research, it showed notable improvements on drug-discovery metrics when compared against base GPT-5.5 models after evaluation on MedChemBench.

From benchmark to bench

One documented example comes from a collaboration with Molecule.one in June 2026. In that work, OpenAI’s GPT-5.4 model was deployed to help run 10,080 reactions aimed at improving yields in a Chan-Lam coupling reaction.

What this means for AI in drug discovery

Because MedChemBench is described as an internal benchmark, and OpenAI’s own models sit at the top, outside researchers will reasonably want to see how the tasks are constructed and scored.

GPT-5.6 Sol at 48.3% and GPT-6 Astra at 49.7% show improvement, though a modest one. Whether future models break meaningfully past the 50% mark, particularly on multi-step reasoning, will say more about AI’s role in drug discovery than any single announcement.

Disclosure: This article was edited by Diego Almada Lopez. For more information on how we create and review content, see our Editorial Policy.